
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography…
Read moreNews & Views
Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer with Positron Emission Tomography…
Read moreNews,
Telix is delighted to announce the appointment of Gabrielle Wermenbol as Chief Financial Officer, Europe, Middle East and Africa…
Read moreNews,
Telix is pleased to announce that Ms. Kyahn Williamson has joined the Telix executive leadership team in the role of Senior Vice President of Corporate Communications and Investor…
Read moreTelix announces that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with bladder…
Read moreTelix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line…
Read moreTelix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product…
Read moreTelix is pleased to announce the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied…
Read moreNews,
Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing…
Read moreAdvanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA…
Read moreTelix is pleased to announce we will be presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Virtual Annual Meeting to be held 11 – 15…
Read more